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GlycosaminoglycanThe enzyme arylsulfatase B (N-acetylgalactosamine 4-sulfatase; ASB; ARSB), which removes 4-sulfate groups
from the nonreducing end of chondroitin-4-sulfate (C4S;CSA) and dermatan sulfate, has cellular effects,
beyond those associated with the lysosomal storage disease mucopolysaccharidosis VI. Previously, reduced
ASB activity was reported in cystic ﬁbrosis patients and in malignant human mammary epithelial cell lines in
tissue culture compared to normal cells. ASB silencing and overexpression were associated with alterations
in syndecan-1 and decorin expression in MCF-7 cells and in IL-8 secretion in human bronchial epithelial cells.
In this report, we present the role of ASB in the regulation of the kininogen–bradykinin axis owing to its
effect on chondroitin-4-sulfation and the interaction of C4S with kininogen. Silencing or overexpression of
ASB in normal rat kidney epithelial cells in tissue culture modiﬁed the content of total sulfated
glycosaminoglycans (sGAGs), C4S, kininogen, and bradykinin in spent media and cell lysates. Treatment of
the cultured cells with chondroitinase ABC also increased the secretion of bradykinin into the spent media
and reduced the C4S-associated kininogen. When ASB was overexpressed, the cellular kininogen that
associated with C4S declined, suggesting a vital role for chondroitin-4-sulfation in regulating the kininogen–
C4S interaction. These ﬁndings suggest that ASB, owing to its effect on chondroitin-4-sulfation, may impact
on the kininogen–bradykinin axis and, thereby, may inﬂuence blood pressure.
Because ASB activity is inﬂuenced by several ions, including chloride and phosphate, ASB activity may provide a
link between salt responsiveness and the bradykinin-associated mechanism of blood pressure regulation.iversity of Illinois at Chicago,
, USA. Tel.: +1 312 569 7826;
B.V.Published by Elsevier B.V.1. Introduction
Inborn deﬁciency of the enzyme arylsulfatase B (N-acetylgalacto-
samine-4-sulfatase; ASB; ASB) is the cause of the lysosomal storage
disease mucopolysaccharidosis (MPS) VI, also known as Maroteaux–
Lamy syndrome. Recent evidence has demonstrated deﬁciency of ASB
in association with other cellular pathophysiology, including reduced
activity in malignant mammary cell lines, in metastatic colonic
epithelial cells, in cystic ﬁbrosis cells, and in patients with cystic
ﬁbrosis [1–4]. Changes in the expression of ASB were associated with
changes in the expression of syndecan-1 and decorin inMCF-7 cells, in
IL-8 secretion and neutrophil migration in bronchial epithelial cells,
and in total sulfated glycosaminoglycan and chondroitin-4-sulfate
content in cultured epithelial cells [2,5,6]. Also, manipulations of
chondroitin-4-sulfation have altered axonal regeneration in spinal
cord lesions in mice [7]. Importantly, ASB appears to be localizednot only in the lysosomes but also in the cell membranes of colonic,
bronchial, cerebrovascular, and hepatic cells [2,6,8,9].
When hypersulfated chondroitin sulfate was substituted for
heparin in solutions used for dialysis patients, increased patient
morbidity and mortality resulted [10–13]. These disastrous clinical
outcomes were attributable to the activation of the kinin–kallikrein
pathway in human plasma, resulting in profound clinical hypotension.
Because increased sulfation of chondroitin was identiﬁed as the cause
of the dialysis-associated hypotension, we hypothesized that varia-
tion in sulfation of naturally present chondroitin might affect blood
pressure regulation. Also, high-molecular weight kininogen was
previously reported to interact with heparin and chondroitin sulfate
in endothelial cells [14,15].
The experiments presented in this report address a mechanistic
association between ASB and hypertension, using as our model of
cultured normal rat kidney epithelial cells. The study ﬁndings
demonstrate that increased ASB activity produces decline in cellular
C4S and C4S-associated high-molecular weight kininogen and
increase of bradykinin in the spent media, thereby suggesting a role
for ASB in the modiﬁcation of the kininogen–bradykinin axis and in
the regulation of blood pressure. Because ASB activity is reported to
vary in response to exposure to chloride and phosphate [3,16,17], as
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associated mechanisms of hypertension and salt-associated mecha-
nisms of blood pressure regulation.
2. Materials and methods
2.1. Cell culture of rat kidney epithelial cells
Normal rat kidney epithelial cells (NRK-E52; ATCC, Manassas, VA)
were grown in DMEM with 10% FBS, at 37 °C, 5% CO2, and 95%
humidity. When cells reached 65%–70% conﬂuence, ASB silencing or
overexpression was performed (see below), and cells were harvested
by scraping.
Spent media from untreated, mock-treated, or treated NRK cells
and NRK cells were collected after 24, 48, 72, or 96 hours of
incubation. The samples were frozen at−20 °C immediately, pending
further analysis. In some of the experiments, the NRK cells in culture
were treated with chondroitinase ABC (1 mU/ml to 1 U/ml; Sigma
Chemical Co., St Louis, MO) or keratanase (1 U/ml; Sigma) for 1 hour
before harvesting.
2.2. Arylsulfatase B (ASB; N-acetylgalactosamine-4-sulfatase) activity
assay
ASB measurements were performed using a ﬂuorometric assay
with the synthetic substrate 4-methylumbilliferyl sulfate (4-MUS), by
a standard method [1,3]. Protein content of the cell homogenate was
measured using BCA™ Protein Assay Kit (Pierce, Rockford, IL). ASB
activity was expressed as nanomole per milligram of protein per hour.
2.3. Silencing and overexpression of ASB
Small interfering RNA (siRNA) to silence ASB was obtained
commercially (Qiagen, Valencia, CA) and tested for speciﬁc effect on
reduction of ASB activity, as reported previously [2,5,6]. For ASB
(NM_000046) silencing, the siRNA sequences were as follows:
Sense: 5′- GGGUAUGGUCUCUAGGCAtt - 3′
Antisense: 5′- UUGCCUAGAGACCAUACCCtt - 3′
The siRNA sequences for the negative control were as follows:
Sense: 5′- UUCUCCGAACGUGUCACGUtt - 3′
Antisense: 5′- ACGUGACACGUUCGGAGAAtt -3′
ASB and control plasmids in pCMV6-XL4 vector were obtained
(Origene) and overexpressed in the NRK cells by transient transfec-
tion using 2 μg of the plasmid and Lipofectamine™ 2000 (Invitrogen,
CA), as previously reported [2,5]. Controls included untransfected
cells and cells transfected with vector only. Cells were incubated for
the stated times in humidiﬁed, 37 °C, 5% CO2 environment, and then
harvested 24 hours after the initiation of silencing or overexpression,
except in the time course experiment.
2.4. Measurement of sulfated glycosaminoglycans (sGAG)
Total sulfated glycosaminoglycans (sGAGs), including chondroitin-
4-sulfate (C4S), chondroitin-6-sulfate, keratan sulfate, dermatan sul-
fate, heparan sulfate, and heparin, were measured in cell lysates
by sulfated GAG assay (Blyscan™, Biocolor Ltd, Newtownabbey,
Northern Ireland), as previously reported [2,5,6]. In this assay, the
cationic dye 1,9-dimethylmethylene blue reacts with the sulfated
GAG to produce a dye–GAG complex. The ratio of the GAG dye-
binding capability to the C4S sulfation level is reported as 1.0:1.0 for
C4S from bovine trachea by this assay. Concentration is expressed as
micrograms per milligram protein of cell lysate.2.5. Immunoprecipitation of cell lysates by chondroitin-4-sulfate (C4S)
antibody
Cell lysates were prepared from NRK cells that had been treated
with siRNA for ASB or ASB plasmid and the appropriate controls for
silencing and overexpression and immunoprecipitated with C4S
antibody (4D1; Santa Cruz Biotechnology, Santa Cruz, CA, or Abnova,
Walnut, CA), as previously described [5,6]. The speciﬁcity of the C4S
antibody was reported previously [5], with a yield of pure C4S of more
than 90%, and with recovery of pure CSE or of C6S in a 90:10 mixture
of C6S/C4S of less than 10%.
2.6. Time course of changes in cellular ASB activity and in C4S content
after knockdown by siRNA
NRK cells were grown to 60% conﬂuence in 12-well plates and
treated with ASB siRNA as described above. After 24, 48, 72, and
96 hours, cells were harvested and measurements of ASB activity and
C4S content were performed, as described above.
2.7. Measurement of bradykinin in the spent media
Bradykinin in the spent media was determined by competitive EIA
(BACHEM, Torrance, CA). In this assay, color development was
inversely proportional to the bradykinin content of the samples.
Fifty microliters of samples or of standards, ranging from 10 pg to
10 ng, 25 µl of biotinylated bradykinin tracer, and 25 µl of rabbit
polyclonal antisera to bradykinin were added into the wells of a 96-
well plate, which were coated with a goat anti-rabbit IgG. Samples
were incubated for 2 hours at room temperature and washed
three times. Then, 100 μl of streptavidin–horseradish peroxidase
(HRP) conjugate was added to each well for 1 hour at room temper-
ature. Color was developed by adding hydrogen peroxide/3,3′,5,5′-
tetramethylbenzidine (TMB) substrate. The reaction was stopped by
2 N HCl, and the color was read at 450 nm in a plate reader (FLUOstar,
BMG Labtech, Cary, NC). The concentrations of bradykinin in the
samples were extrapolated from the standard curve and expressed as
picograms per milligram of total cell protein.
2.8. Assay of cellular kininogen bound to C4S
A 96-well ELISA plate was coated overnight at room temperature
with speciﬁc antibody to C4S at a concentration of 4 µg/ml. After
coating, the wells were washed three times with wash buffer (PBS
with Tween-20 0.05%) and blocked for 1 hour at room temperature
with blocking buffer (1% BSA in PBS). One hundred microliters of NRK
cell lysates, including control cell lysates, cells inwhich ASBwas silenced,
cells in which ASB was overexpressed, and cells treated with chondroi-
tinase ABC (1mU/ml, 10 mU/ml, 25 mU/ml, or 1 U/ml×1 hour), was
added to the coated wells and incubated for 2 hours at room tem-
perature. Wells were washed three times and high-molecular weight
kininogen (HMWK) antibody (rabbit polyclonal IgG, 100 µl at a
concentration of 1 µg/ml; H-70, SCBT) was added, and preparations
were incubated for 2 hours at room temperature. This antibody
recognizes the epitope from AA:261–330 of HMWK. Next, goat anti-
rabbit IgG-HRP (100 μl at a concentration of 1:1000) was added to each
well, and the plate was then incubated for 1 hour at room temperature.
Color was developed by adding 100 µl of hydrogen peroxide/TMB
substrate, the reactionwas stopped by 2 NHCl, and the color was read at
450 nm in a microplate reader (BMG).
The speciﬁcity of the assay was determined by several control
experiments. In some control wells, exogenous C4S (Blyscan) at a
concentration of 10 µg/ml was added as a competitive, control assay.
In these wells, the exogenous C4S competed with cellular C4S for the
C4S antibody coated onto the wells, consistent with the speciﬁcity of
the antibody–antigen reaction. In these wells, reduced binding of the
Fig. 1. ASB activity, sGAG, and C4S in rat kidney epithelial cells. (A) In the NRK epithelial
cells, ASB activity at baseline was 163±3 nmol/mg protein/hour. Activity increased
signiﬁcantly after overexpression (to 245±18 nmol/mg protein/hour) and decreased
signiﬁcantly after silencing by siRNA (to 29±1 nmol/mg protein/hour) at 24 hours.
Differences in activity after silencing and overexpression are statistically signiﬁcant
(pb0.001, n=3). One-way ANOVA with Tukey–Kramer posttest was used for deter-
minations of statistical signiﬁcance, unless stated otherwise. control si = control siRNA;
ASB si= arylsulfatase B siRNA; Vcontrol = vector control for overexpression; ASB OE=
arylsulfatase B overexpression. (B) Inversely, the total sGAG increased after ASB
silencing for 24 hours (from 10.2±0.2 to 18.1±1.7 μg/mg protein; pb0.001, n=3)
and decreased after ASB overexpression for 24 hours (to 5.5±0.5 μg/mg protein;
pb0.001, n=3). sGAG = sulfated glycosaminoglycans. (C) Changes in chondroitin-4-
sulfate (C4S) content largely accounted for the changes in total sGAG after ASB silencing
for 24 hours (from 5.5±0.4 to 12.6±1.2 μg/mg protein; pb0.001, n=3) or ASB
overexpression for 24 hours (to 1.0±0.1 μg/mg protein; pb0.001, n=3) at 24 hours.
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kininogen complex would be bound to the C4S antibody. In some
wells, treatment with keratanase (1 U/ml×1 hour) was used as a
control enzymatic digestion that, unlike chondroitinase ABC, was not
expected to hydrolyze bonds of C4S and to not change the amount of
kininogen bound to C4S. To exclude nonspeciﬁc binding of kininogen
antibody to the cell lysates, normal rabbit serum was added to some
wells instead of kininogen antibody.
The OD data for cellular kininogen bound to C4S are presented as
percent control, in which control is the cell lysate that was not
exposed to chondroitinase ABC, to silencing or overexpression of ASB,
to keratanase, or to exogenous C4S.
2.9. Assay for kininogen in NRK spent media
A 96-well ELISA plate was coated overnight at room temperature
with an antibody to high molecular weight kininogen (HMWK; H-70,
SCBT) at a concentration of 4 µg/ml. After coating, the cells were
washed three times with wash buffer (PBS with Tween-20 0.05%) and
blocked for 1 hour at room temperature with blocking buffer (1% BSA
in PBS). One hundred microliters of deproteinized spent media with
no added serumwas added to the coatedwells, and preparations were
incubated for 2 hours, then washed three times, prior to adding 100 µl
of a second kininogen antibody (M-20, SCBT), at a concentration of
1 µg/ml and incubating for 2 hours at room temperature. Neither of
the kininogen antibodies was directed at the bradykinin nonapeptide
(AA:381–389 AA). Preparations were washed three times, and 100 µl
of donkey anti-goat IgG–HRP at 1:1000 dilution was added before
incubation for 1 hour at room temperature. Color was developed by
adding 100 µl of hydrogen peroxide/TMB substrate; the reaction was
stopped by 2 N HCl, and color was read at 450 nm in a microplate
reader (BMG).
2.10. Confocal microscopy
For confocal microscopy, NRK cells were grown in 4-chamber tissue
culture slides for 24 hours, and staining methods that have been
previously described were performed [2,6,8]. Cells were ﬁxed in 2%
paraformaldehyde for 90 minutes, washed once in 1× PBS containing
1 mMcalciumchloride (pH7.4), and permeabilizedwith 0.08% saponin.
Slides were washed again with PBS, blocked in 5% normal goat serum,
and incubated overnight with high-molecular weight kininogen
(HMWK) rabbit polyclonal antibody (H-70, SCBT; 1:25) and C4S anti-
body (4D1; SCBT; 1:25) at 4 °C. Slides were washed and stained with
goat–anti-rabbit Alexa Fluor® IgG 568 (1:100; Invitrogen) and Alexa
Fluor® 488 (1:100; Invitrogen), and coverslipped using DAPI-mounting
medium (Vectashield®; Vector Laboratories, Inc., Burlingame, CA) for
nuclear staining. Stained cells were observed with a Zeiss LSM 510
laser scanning confocal microscope (excitation of 488 nm and 534 nm
from an Ar/Kr laser). Green (HMWK) and red (C4S) ﬂuorescence were
detected through LP505 and 585 ﬁlters and scanned sequentially, and
collected imageswere exportedbyZeiss LSM ImageBrowser software as
TIFF ﬁles for analysis and reproduction.
2.11. Statistics
Results are the mean±SD of at least three biological determina-
tions with two technical replicates of each. Statistical signiﬁcance was
determined by one-way ANOVA followed by Tukey–Kramer posttest
to correct for multiple comparisons using InStat3 software (GraphPad,
San Diego, CA), unless stated otherwise. When experiments were
repeated more than three times, the ﬁgures present the mean of three
representative, independent experiments and their technical repli-
cates. A p value of b0.05 is considered statistically signiﬁcant. In the
ﬁgures, ⁎⁎⁎pb0.001, ⁎⁎p≤0.01, and ⁎p≤0.05.3. Results
3.1. ASB activity, sGAG, and C4S in rat kidney epithelial cells
The enzyme arylsulfatase B (ASB) was silenced and overexpressed
in normal rat kidney epithelial cells (NRK) in cell culture, and cells,
with appropriate controls, were harvested after 24 hours. ASB activity
changed signiﬁcantly from baseline after silencing (pb0.001) and
overexpression (pb0.001) (Fig. 1A).
The total cellular sGAGs, including chondroitin-4-sulfate (C4S),
chondroitin 6-sulfate, dermatan sulfate, keratan sulfate, heparin, and
heparan sulfate, were also measured in these same preparations
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changes in sGAG content occurred.
Next, control and treated NRK cell lysates were immunoprecipi-
tated with C4S antibody, and the sGAG was measured (Fig. 1C). Total
C4S increased after ASB silencing (pb0.001) and declined after ASB
overexpression (pb0.001), consistent with the anticipated modiﬁca-
tions of C4S content by changes in ASB activity.
3.2. Time course of decline in ASB activity and increase in C4S after ASB
siRNA
ASB activity declined maximally by 24 hours and remained at 15%
of baseline for 72 hours, then rose somewhat to 45% of baseline
activity by 96 hours (Fig. 2A). C4S increased rapidly by 24 hours and
peaked at 2.3 times the baseline. The increase was sustained for
at least 2 days (Fig. 2B). By 96 hours, C4S content declined some-
what to 1.7 times the baseline value, consistent with the rise in ASB
activity. All changes from baseline values were statistically signiﬁcant
(pb0.001).
3.3. Effects of ASB expression and chondroitinase ABC treatment on
bradykinin
Because we hypothesized that bradykinin release from the NRK
cells was affected by changes in the C4S content, we measured
bradykinin in the spent media after ASB silencing and overexpression
(Fig. 3A). Bradykinin in the spent media increased from 63±5 pg/mg
cell protein to 208±13 pg/mg cell protein after ASB overexpression
(pb0.001) but did not decline after ASB silencing. These results
suggest that only increased ASB activity with resultant reduction inFig. 2. Time course of decline in ASB activity and of associated increase in C4S after ASB
silencing. (A) ASB was silenced by siRNA, and ASB activity was measured at 24, 48, 72,
and 96 hours after silencing. Maximum decline in ASB activity occurred by 24 hours
(to 24±1 nmol/mg protein/hour from baseline 165±16 nmol/mg protein/hour) and
persisted for 72 hours at 15% of the baseline activity level. By 96 hours, ASB activity had
started to rise and was 45% of baseline. All declines were statistically signiﬁcant
(pb0.001, n=3). (B) C4S rose to its maximum (13.3±0.2 μg/mg protein) by 48 hours
and remained at this level at 72 hours but began to return to baseline by 96 hours (10.0±
0.2 μg/mg protein). C4S rise followed the ASB decline. All increases in C4S are statistically
signiﬁcant (pb0.001, n=3).
Fig. 3. Bradykinin content in spent media increased after ASB overexpression or
chondroitinase ABC treatment. (A) Baseline bradykinin content released into the spent
media was 63.0±5.0 pg/mg cell protein. Overexpression of ASB for 24 hours produced
a signiﬁcant increase, to 207.6±13.1 pg/mg cell protein (pb0.001). When ASB was
silenced for 24 hours in the NRK cells, no change in bradykinin in the spent media was
observed. (B) When living NRK cells in cell culture were treated with chondroitinase
ABC (1 U/ml×1 hour) and then harvested and the spent media was collected, the
content of bradykinin in the spent media increased signiﬁcantly (pb0.001, n=3),
compared to media from untreated cells. Treatment with keratanase (1 U/ml×1 hour),
which hydrolyzes bonds in keratan sulfate, had no effect. Results are consistent with
cellular C4S inhibiting the release of bradykinin (or a bradykinin precursor) into the
spent media. ChABC = chondroitinase ABC. (C) Increased bradykinin in the spent
media was evident after treatment of the NRK cells with increasing concentrations of
chondroitinase ABC (from 1 to 25 mU/ml×1 hour). Little further increase occurred
between concentrations of 25 mU/ml and 1 U/ml.chondroitin-4-sulfation had an impact on bradykinin release from the
NRK cells.
To address further the underlying mechanism by which ASB and
C4S might affect bradykinin content in the spent media, NRK cell
preparations were treated with chondroitinase ABC (Fig. 3B). The
bradykinin content of the spent media increased from 66±4 pg/mg
cell protein to 229±23 pg/mg cell protein (pb0.001) after expo-
sure of the living cells to chondroitinase ABC (1 U/ml×1 hour),
suggesting a profound effect of chondroitinase ABC treatment on
Fig. 4. Chondroitin 4-sulfate (C4S) associated-kininogen declined after ASB over-
expression or chondroitinase ABC treatment. (A) Kininogen associated with C4S was
measured in the NRK cell lysates after ASB silencing or overexpression×24 hours.
When ASB was overexpressed for 24 hours, kininogen associated with C4S in the cell
preparation declined signiﬁcantly, to 25±2% of baseline (pb0.001, n=3). In contrast,
but consistent with the lack of impact of ASB silencing on bradykinin in the spent
media, ASB silencing had no effect on the content of C4S-associated kininogen. (B) The
NRK cell lysate was treated with chondroitinase ABC (1 U/ml×1 hour) and assayed for
kininogen that was associated with cellular C4S. The cellular C4S was captured by
binding to C4S antibody, which coated the bottom of wells of a microtiter plate. The
C4S-associated kininogen declined to 32±2% of baseline after chondroitinase ABC
treatment (pb0.001, n=3). Competition with free C4S (10 μg/ml) further reduced the
C4S-bound kininogen, to 9±0.5% of baseline (pb0.001, n=3). (C) Increasing
concentrations of chondroitinase ABC (from 1 to 25 mU/ml×1 hour) produced
progressive declines in the C4S-bound kininogen. Little difference was found between
exposure to chondroitinase ABC 25 mU/ml and 1 U/ml×1 hour.
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(1, 10, or 25 mU/ml) (Fig. 3C) produced smaller, but signiﬁcant
increases of bradykinin in the spent media (pb0.001).
When the spent media were assayed for kininogen by a sandwich
assay that utilized two different antibodies to kininogen, neither of
which included the bradykinin nonapeptide in their epitope, as
described in Section 2, no kininogen was demonstrated in the spent
media.
3.4. C4S-associated kininogen declined after ASB overexpression and
chondroitinase ABC treatment
The content of kininogen associated with C4S in NRK cell lysates
after ASB silencing and overexpression was assessed by a plate assay
inwhich thewells were coatedwith C4S antibody. After ASB silencing,
no change in the C4S-associated kininogen content was detected,
consistent with the lack of impact of ASB silencing on the bradykinin
content in the spent media (Fig. 4A). In contrast, after ASB over-
expression, the cellular kininogen content declined signiﬁcantly
(pb0.001), consistent with the observed increase in bradykinin in
the spent media.
The content of kininogen associated with C4S in the NRK cell
lysates was also determined after treatment with chondroitinase
ABC (Fig. 4B). Marked decline in the cellular kininogen content was
demonstrated after chondroitinase ABC (1 U/ml×1 hour; pb0.001),
in contrast to no effect of keratanase treatment. When exogenous C4S
competed with the C4S in the NRK cell lysate for binding to the C4S
antibody coating in the plate assay, NRK cell lysate binding declined to
9% of the baseline value (pb0.001).
In the cell lysates treated with increasing concentrations of
chondroitinase ABC (Fig. 4C), the C4S-associated kininogen progres-
sively declined with exposure to increasing concentrations of
chondroitinase ABC (from 1 to 25 mU/ml×1 hour). No further
increase in the effect occurred with a higher dose of chondroitinase
ABC (1 U/ml×1 hour). The similarity between the effects of treat-
ment with chondroitinase ABC and ASB overexpression on cellular
kininogen content demonstrates that ASB has a signiﬁcant impact on
the integrity of the cellular C4S.
3.5. Colocalization of C4S and kininogen
Confocal microscopy was performed on NRK cells grown for
24 hours in chamber slides. As presented in Fig. 5, immunoﬂuorescent
staining indicates merging of the images of kininogen (green, A) and
C4S (red, B), demonstrating their colocalization (yellow, D). These
results are consistent with other study ﬁndings that demonstrate the
association of kininogen with C4S in the NRK cells.
4. Discussion
The study ﬁndings demonstrate increases in total cellular sGAG
and C4S after silencing of ASB and declines in total cellular sGAG and
C4S after overexpression of ASB in normal rat kidney epithelial (NRK)
cells. In associationwith declines in cellular C4S when the ASB activity
was increased by overexpression, bradykinin in the spent media
increased and cellular kininogen declined. These ﬁndings are
consistent with the hypothesis that changes in chondroitin-4-
sulfation that follow changes in ASB activity may have a role in
regulation of the kininogen–bradykinin axis.
The Rat Genome Database maps several Quantitative Trait Loci
(QTLs) in the vicinity of ASB (Chromosome 2, from 24067560 to
24223821) that have been associated with blood pressure [18]. These
include the following QTLs: 115, 243, 18, 36, 270, and 240. Also,
several genes related to kidney mass (QTLs: 27, 28, 24, and 23) and
cardiac mass (QTLs: 41, 42, 39, and 38) map to this ASB region, sug-gesting relevant relationships to renal and cardiac pathophysiology,
as well as to blood pressure in the rat genome.
Mechanisms of hypertension are complex, and the regulation of
blood pressure requires the interplay of multiple vital substrates
and receptors. The experiments in this report present evidence that
suggests that the enzyme ASB, bymodiﬁcation of cellular chondroitin-
4-sulfation, may exert a profound effect on blood pressure by
Fig. 5. Confocal microscopy colocalizes C4S and kininogen in NRK cells. Fluorescent
immunostaining demonstrates colocalization of C4S and kininogen. (A) Kininogen in
green. (B) C4S in red. (C) DAPI (blue)-stained nuclei. (D) Merged yellow staining where
kininogen and C4S have colocalized in the cytoplasm of the NRK cells.
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affecting the production/release of bradykinin. The speciﬁc molecular
interactions between C4S and kininogen, although critical to
understanding the production of bradykinin from kininogen, are
beyond the scope addressed in this report.
The production of systemic hypotension, when oversulfated
chondroitin sulfate was substituted for heparin during hemodialysis
[10–13], provided the basis for further consideration of the effects of
chondroitin-4-sulfation and ASB activity on bradykinin availability.
Recent Biacore experiments, designed to elucidate further the
interaction between sGAG and the kininogen–bradykinin axis,
conﬁrm an association between oversulfated chondroitin sulfate,
heparin, plasma kallikrein, high-molecular weight kininogen
(HMWK), and factor XII [19]. Increased production of bradykinin
was hypothesized to arise from the favorable geometric orientation in
the circulation of bradykinin, kininogen, and kallikrein, in association
with sGAG and factor XII.
Although biotinylated-C4S did not produce similar results in the
Biacore experiments as heparin and oversulfated chondroitin sulfate,
additional factors, including the proteins to which C4S is bound in vivo
and other differences in the cellularmicroenvironment in vitro, as well
as the chemical interaction required for biotin binding, may explain
how the Biacore result differs from the ﬁndings in the experi-
ments that we have performed, which suggest the importance of the
C4S–kininogen interaction.
The association between kininogen and C4S appears to be
greater when ASB activity is lower and may be attributable to the
presence of the 4-sulfate groups of C4S. In other works, increases in
C4S disaccharides were demonstrated, after decline in ASB activity
[6,8], as expected by the established mechanism of action of ASB
[20,21].
Because chloride, as well as sulfate, sulﬁte, and phosphate, is
reported to reduce ASB activity [3,16,17], it is possible that increased
chloride due to high salt intake may contribute to reduction of ASBactivity in vivo. Reduced ASB activity might then lead to increased
chondroitin-4-sulfation, increased binding of kininogen, and reduced
bradykinin release. These interactions suggest a mechanism for an
interrelationship between salt and bradykinin in the regulation of
blood pressure. This innovative approach into mechanisms of
hypertension may help to establish effective, individualized regimens
for blood pressure control.
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